全文获取类型
收费全文 | 27749篇 |
免费 | 1716篇 |
国内免费 | 195篇 |
专业分类
耳鼻咽喉 | 132篇 |
儿科学 | 804篇 |
妇产科学 | 1079篇 |
基础医学 | 1688篇 |
口腔科学 | 417篇 |
临床医学 | 4170篇 |
内科学 | 4784篇 |
皮肤病学 | 236篇 |
神经病学 | 1730篇 |
特种医学 | 857篇 |
外科学 | 5336篇 |
综合类 | 1266篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 4133篇 |
眼科学 | 297篇 |
药学 | 1142篇 |
33篇 | |
中国医学 | 125篇 |
肿瘤学 | 1428篇 |
出版年
2024年 | 69篇 |
2023年 | 1858篇 |
2022年 | 2452篇 |
2021年 | 2474篇 |
2020年 | 2789篇 |
2019年 | 1498篇 |
2018年 | 1291篇 |
2017年 | 1309篇 |
2016年 | 1328篇 |
2015年 | 1240篇 |
2014年 | 2419篇 |
2013年 | 1709篇 |
2012年 | 1283篇 |
2011年 | 942篇 |
2010年 | 1332篇 |
2009年 | 1262篇 |
2008年 | 592篇 |
2007年 | 588篇 |
2006年 | 468篇 |
2005年 | 325篇 |
2004年 | 228篇 |
2003年 | 225篇 |
2002年 | 208篇 |
2001年 | 242篇 |
2000年 | 195篇 |
1999年 | 212篇 |
1998年 | 215篇 |
1997年 | 149篇 |
1996年 | 172篇 |
1995年 | 164篇 |
1994年 | 93篇 |
1993年 | 56篇 |
1992年 | 41篇 |
1991年 | 44篇 |
1990年 | 44篇 |
1989年 | 41篇 |
1988年 | 63篇 |
1987年 | 11篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1975年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
53.
54.
55.
《Diagnostic microbiology and infectious disease》2020,96(1):114920
We evaluated the performance of the Luminex ARIES® C. difficile Assay on 984 stool specimens prospectively collected from patients being tested for CDI at 4 clinical laboratories in the United States. Results were compared to direct and enriched toxigenic culture. Positive percent agreement (PPA) of the ARIES® C. difficile Assay was 98.1% versus direct toxigenic culture, and sensitivity versus direct plus enriched toxigenic culture was 90.5%. Negative percent agreement (NPA) of the ARIES® C. difficile Assay against direct culture was 92.6%, and specificity versus direct plus enriched toxigenic culture was 95.8%. The ARIES® C. difficile Assay was also compared to the results of routine (molecular, antigen, and/or toxin) methods for C. difficile testing used at each institution. The PPA of the ARIES® C. difficile Assay ranged from 82.9% to 100%. NPA values against these commercial assays ranged from 94.5% to 100%. 相似文献
56.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):25-34
PurposeTo investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A–B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses.ResultsThe median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6–11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1–3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9–23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6–26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2–7.2), and progression-free survival was 5.7 months (95% CI, 4.3–7.1).ConclusionsRadioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy. 相似文献
57.
58.
59.
《Transplantation proceedings》2019,51(6):1956-1961
BackgroundNew-onset diabetes after transplant is a severe complication that can present in liver transplant recipients, negatively impacting quality of life and graft survival. It also contributes to increased risk of infection, cardiovascular disease, and rejection, which are the main causes of death among liver transplant recipients. The aim of the present study was to assess the risk factors associated with new-onset diabetes after transplant.MethodThis was a case control study based on the data from 146 liver transplant patients at a reference hospital. The data from the charts were collected using a 2-part form: Part I (sociodemographic variables) and Part II (clinical variables).ResultsMultiple analysis showed that pre-existing systemic arterial hypertension (odds ratio [OR], 2.65; 95% CI, 1.12–6.28) and the use of sodium mycophenolate associated with tacrolimus (OR, 2.68; 95% CI, 1.02–7.06) increased the risk of new-onset diabetes after transplant. On comparing the anthropometric variables, lipid panel, and blood glucose levels of liver transplant patients with and without diabetes, higher glycemic levels were found in the group with diabetes (P < .001).ConclusionPre-existing systemic arterial hypertension and the associated use of sodium mycophenolate and tacrolimus increased the risk of new-onset diabetes after transplant. 相似文献
60.